![\"astrazeneca\"](\"http:\/\/s.wsj.net\/public\/resources\/images\/OB-HW375_bus_D_20100316113743.jpg\")
AstraZeneca lifted the veil a bit today on its plans to become a bigger player in emerging markets, saying sales in those those countries will double to account for about a quarter of the British company’s total revenue by 2014.<\/p>\nAstraZeneca lifted the veil a bit today on its plans to become a bigger player in emerging markets, saying sales in those those countries will double to account for about a quarter of the British company’s total revenue by 2014.<\/p>\n
Branded generics will be a part of its push, the company said, but they will only account for 10% to 15% of its emerging-market sales by 2014. Because it isn’t willing to take a big hit on pricing, AstraZeneca said it would be “very selective” in branded generics, targeting around 100 medicines for sale in 30 markets where it can achieve favorable margins. <\/p>\n
The company cited forecasts that emerging markets are expected to contribute around 70% of pharma-industry growth in the next five years, with branded generics accounting for a large chunk of that expansion. AstraZeneca last week announced generic supply deal<\/a> for emerging markets with India’s Torrent Pharmaceuticals. Terms weren’t disclosed.<\/p>\n Of course, other companies including, Pfizer<\/a>, GlaxoSmithKline<\/a> and Eli Lilly<\/a> also have their sights set on emerging markets and on branded generics in particular. Indeed, Reuters<\/a> notes that while AstraZeneca is shooting for a quarter of its sales coming from emerging markets, European rivals such as Sanofi-Aventis, Novartis and Bayer are there already.<\/p>\n Here’s more from Dow Jones Newswires<\/a>.<\/p>\n Photo: AstraZeneca<\/em><\/p>\n AstraZeneca lifted the veil a bit today on its plans to become a bigger player in emerging markets, saying sales in those those countries will double to account for about a quarter of the British company’s total revenue by 2014. Branded generics will be a part of its push, the company said, but they will […]<\/p>\n","protected":false},"author":792,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-435807","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/435807","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/792"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=435807"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/435807\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=435807"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=435807"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=435807"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}<\/img><\/a>
\n<\/img><\/a><\/p>\n
\n<\/img><\/a>
<\/img><\/a>
<\/img><\/a>
<\/img><\/a>
<\/img><\/a>\n<\/div>\n
<\/p>\n","protected":false},"excerpt":{"rendered":"